Crinetics announces results from Phase 2 trial of atumelnant

Crinetics (CRNX) Pharmaceuticals announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia, CAH, study of investigational atumelnant, a novel, once-daily oral adrenocorticotropic hormone, ACTH, receptor antagonist candidate being developed for the treatment of classic CAH and ACTH-dependent Cushing’s syndrome. For all doses, treatment with atumelnant resulted in rapid, substantial and sustained statistically significant reduction in A4 levels, the key biomarker for disease control. Additionally, rapid, substantial and sustained statistically significant reductions in 17-OHP, a confirmatory secondary biomarker of disease control, were achieved across doses. Treatment with atumelnant also had a significant impact on CAH signs and symptoms, including: Substantial reduction and normalization of testosterone in the majority of female participants,1 with 6 of the 11 impacted participants resuming menses; Consistent reduction in total adrenal volume observed across dose cohorts; Resolution of androgen mediated polycythemia in 5 of the 6 impacted participants